Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.10/Share

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.10), versus ($0.21) reported last year. Revenue for the quarter came in at $424 thousand, versus $247 thousand reported last year.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• S&P 500 may pull back before midterms, but Citi says buy the dip